Three months after receiving a personalized dose of radioactive iodine for Graves' disease, two-thirds of patients became hypothyroid and needed daily thyroid hormone pills, while one-third had normal thyroid function; by six months, everyone had normal thyroid function with medication.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
The pooled rate of hypothyroidism and euthyroidism at 3 and 6 months after dosimetry-based RAI in Graves' disease across diverse populations.
A systematic review and meta-analysis of all prospective cohort studies and RCTs reporting thyroid function outcomes at 3 and 6 months after dosimetry-based RAI (targeting 200 Gy) in adults with Graves' disease, stratified by age, thyroid volume, and antithyroid drug use.
Whether dosimetry-based RAI leads to a different rate of hypothyroidism at 3 months compared to fixed-dose RAI in Graves' disease.
A double-blind RCT of 150 adults with Graves' disease randomized to dosimetry-based RAI (200 Gy target) or fixed-dose RAI (555 MBq), with primary outcome: proportion developing hypothyroidism at 3 months, measured by TSH >10 mIU/L and low fT4.
The natural history of thyroid function after dosimetry-based RAI in Graves' disease over time.
A prospective cohort of 300 patients with Graves' disease treated with dosimetry-based RAI (200 Gy target), followed with monthly thyroid function tests for 6 months, then quarterly for 2 years, to document progression to hypothyroidism or euthyroidism.
Whether baseline thyroid volume or iodine uptake predicts early hypothyroidism after dosimetry-based RAI.
A case-control study comparing 50 patients who became hypothyroid at 3 months with 100 who remained euthyroid after dosimetry-based RAI, analyzing pre-treatment thyroid volume, uptake percentage, and TSH receptor antibody levels.
The current prevalence of hypothyroidism among patients who received dosimetry-based RAI for Graves' disease at least 6 months prior.
A cross-sectional survey of 200 patients treated with dosimetry-based RAI for Graves' disease at least 6 months ago, measuring current TSH, fT4, and levothyroxine use.